MindWalk Holdings Corp.

NASDAQ:HYFT

Biotechnology

Healthcare
$1.08 +0.33%

+$0.01 today

Market cap
$50.88M
Beta
0.82
P/E (TTM)
-8.1
EPS (TTM)
-$0.26
52W Low $0.82High $3.25

Volume 0.20M

Average 0.32M

HYFT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

MindWalk Holdings Corp.NASDAQ: HYFT

Research & Development · Q3 FY2026 · quarter ended Jan 2026

Research & development growth accelerates

Q3 FY2026 research & development of CA$1.19M rose 13.0% year over year, ahead of the +1.7% change in trailing-twelve-month research & development. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at -13.6% a year.

Context

  • Research & development amounted to 20.2% of revenue in FY2025, up 3.7 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +13.0% holds above the trailing-twelve-month pace of +1.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
CA$1.19M-2.5% QoQ
Last fiscal yearApr 2025
CA$4.94M+22.3% YoY
LTMJan 2026
CA$4.56M+1.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.0%——
1 year+22.3%——
3-year CAGR-13.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
4.94M CAD
Year-over-year change
+22.3%
4-year CAGR
+25.8%

Research & Development vs competitors

How HYFT compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.7% is the 3rd highest of 9, against a peer median of -12.1%.
  • Research & development amounts to 24.8% of revenue for HYFT, versus a peer median of 5277.2%.
HYFT Competitors
Research & Development for HYFT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$70.7M USD-6.3%+29.5%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M USD-38.5%-7.9%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$55.72M USD+5.5%+12.0%29327.4%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$37.7M USD-3.9%—958.2%
CLNNClene Inc.LTM Mar 2026$12.86M USD-17.9%-24.0%9596.3%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$8.57M USD-44.2%-9.8%—
FBIOFortress Biotech, Inc.LTM Mar 2026$8.51M USD-76.4%-55.5%12.9%
BYSIBeyondSpring Inc.LTM Mar 2026$4.59M USD+218.0%-44.4%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$4.56M CAD+1.7%-13.6%24.8%
Peer median (excluding HYFT) —-12.1%-9.8%5277.2%

Competitors are the stored peer set for HYFT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue17.91M19.36M20.67M24.52M24.52M
Cost of Revenue6.37M8.38M9.1M12.47M10.97M
Gross Profit11.54M10.98M11.56M12.05M13.55M
Gross Margin64.4%56.7%56.0%49.2%55.3%
Research & Development1.97M7.66M14.1M4.04M4.94M
Selling, General & Admin13.27M18.06M18.99M19.14M19.03M
Operating Expenses15.71M27.66M37.17M25.82M25.74M
Depreciation & Amortization3.71M3.77M6.69M5.74M5.12M
EBITDA(1.42M)(11.99M)(21.04M)(22.95M)(28.86M)
EBITDA Margin-7.9%-61.9%-101.8%-93.6%-117.7%
Operating Income(4.18M)(16.67M)(25.61M)(13.76M)(12.2M)
Operating Margin-23.3%-86.1%-123.9%-56.1%-49.7%
Interest Income265.01K279K122K23K0
Interest Expense602.37K85K30K19K9.91K
Other Income / Expenses(1.82M)825K(2.14M)(14.94M)(22.07M)
Income Before Tax(6M)(15.85M)(27.75M)(28.7M)(34.27M)
Pre-Tax Margin-33.5%-81.8%-134.3%-117.1%-139.8%
Income Tax Expense1.35M861K(1.19M)(2.59M)(4.03M)
Net Income(7.34M)(16.71M)(26.56M)(26.12M)(30.23M)
Net Margin-41.0%-86.3%-128.5%-106.5%-123.3%
EPS (Basic)(0.45)(0.87)(1.07)(1.03)(0.90)
EPS (Diluted)(0.45)(0.87)(1.07)(1.03)(0.90)
Weighted Avg Shares16.47M19.69M24.9M25.64M33.39M
Weighted Avg Shares (Diluted)16.47M19.69M24.9M25.64M33.39M

MindWalk Holdings Corp.

NASDAQ:HYFT

Intrinsic Alpha fair value

Locked

Current Price

$1.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.